Q2 2018 13F Holders as of 30 Jun 2018
-
Type / Class
-
Debt / DBCV 0.250% 2/0
-
Market price (% of par)
-
92.7%
-
Total 13F principal
-
$421,217,914
-
Principal change
-
+$18,069,629
-
Total reported market value
-
$390,674,628
-
Number of holders
-
55
-
Value change
-
+$17,073,301
-
Number of buys
-
20
-
Number of sells
-
21
Institutional Holders of TEVA PHARMACEUTICAL FIN LLC - DBCV 0.250% 2/0 as of Q2 2018
As of 30 Jun 2018,
TEVA PHARMACEUTICAL FIN LLC - DBCV 0.250% 2/0 was held by
55 institutional
bondholders
reporting positions in Form 13F filings.
These institutions reported holding
$421,217,914
in principal (par value) of the bond.
The largest 10 bondholders included
Allianz Asset Management GmbH, PRUDENTIAL PLC, WELLS FARGO & COMPANY/MN, ADVENT CAPITAL MANAGEMENT /DE/, CAPSTONE INVESTMENT ADVISORS, LLC, Southpaw Asset Management LP, OAKTREE CAPITAL MANAGEMENT LP, CITADEL ADVISORS LLC, INCOME RESEARCH & MANAGEMENT, and AXA.
This page lists
55
institutional bondholders reporting positions
for the Q2 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price (% of par)
|
Principal |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.